Arrowhead Research has acquired Novartis’ entire RNAi R&D portfolio and associated assets. The acquisition includes certain patents and patent applications related to RNAi therapeutics, an exclusive license in the RNAi field to other patents and patent applications owned or controlled by Novartis, assignment of a third party license, three preclinical RNAi candidates, and other related assets. Novartis received $7 million in cash and will receive an additional payment of $3 million in cas...